Grace Therapeutics, Inc. (GRCE)
2025-06-30 | ||||
|---|---|---|---|---|
| Income tax benefit | - | |||
| Research and development expenses | 955 | |||
| General and administrative expenses | 2,135 | |||
| Loss from operating activities | -3,090 | |||
| Interest and other income, net | 205 | |||
| Foreign exchange gain (loss) | 10 | |||
| Change in fair value of derivative warrant liabilities | 487 | |||
| Other (expense) income, net | -272 | |||
| Loss before income tax benefit | -3,362 | |||
| Net loss | -3,362 | |||
| Basic loss per share (in dollars per share) | -0.21 | |||
| Diluted loss per share (in dollars per share) | -0.21 | |||
| Weighted average number of shares outstanding, diluted (in shares) | 15,924,522 | |||
| Weighted average number of shares outstanding. basic (in shares) | 15,924,522 | |||